ABSTRACT
BACKGROUND: Retrospective studies in hematological unit have suggested that single red blood cell (1-RBC) unit transfusion policy may reduce the number of RBC used without negative clinical impact. METHOD: Acute leukemia patients requiring intensive chemotherapy or patients receiving autologous or allogeneic transplantation were randomly assigned to receive either single RBC (1-RBC arm) or double RBC (2-RBC arm) per transfusion with a hemoglobin trigger of 8 g/dL. The primary composite endpoint was the percentage of patients experiencing serious complications, such as a non-hematological adverse event grade ≥ 3 or intensive care admission or death. FINDINGS: A total of 981 and 592 RBC transfusions were required in the 1-RBC arm (n = 125) and the 2-RBC arm (n = 120), respectively. The mean pre-transfusion hemoglobin levels were 7.49 ± 0.83 g/dL in the 1-RBC arm and 7.46 ± 0.67 g/dL in the 2-RBC arm (p = 0.275). The predefined non-inferiority criteria was achieved with 28/125 patients reaching the primary endpoint in the 1-RBC arm (22.4 %) and 28/120 patients in the 2-RBC arm (23.3 %) (Risk difference 0.009; 95 %, Confidence interval [-0.0791 to 0.0978], p = 0.021). The median (IQR) of RBC units transfused per patient was 7 (4-12) in the 1-RBC arm and 8 (4-12) in 2-RBC arm. Hemoglobin levels at discharge were also comparable in both arms. INTERPRETATION: The results of this trial indicate that a single RBC transfusion policy is not inferior to a double RBC transfusion policy for patients receiving a bone marrow transplant or intensive chemotherapy in a hematological intensive care unit. However, the single RBC transfusion policy did not reduce the number of RBC units transfused per stay. FUNDING: This trial was funded by a grant from the French Ministry of Health.
Subject(s)
Hematologic Diseases , Leukemia, Myeloid, Acute , Humans , Retrospective Studies , Erythrocyte Transfusion/adverse effects , Hemoglobins , Leukemia, Myeloid, Acute/etiology , Acute DiseaseABSTRACT
Splenectomy remains the preferred treatment for chronic immune thrombocytopenia (ITP) after corticosteroid failure, despite the risks of despite surgical complications and infection. The aim of this study was to assess the efficacy of and tolerance to rituximab through a retrospective analysis of 35 refractory/relapsing ITP patients treated from 2004 to 2013. The median age of subjects was 46 years (14-80). Rituximab was given at a weekly dose of 375 mg/m(2) for 4 weeks. Median time from diagnosis to first infusion was 17 months (1-362) and follow-up was 47 months (2-133). The overall response rates at 1 and 2 years after the first infusion were 47 and 38 %, with complete response rates of 24 and 25 %, respectively. Median duration of response was 38 months (1-123), with 37 % of patients maintaining a durable response (>1 year). Twenty-nine percent of patients had undergone splenectomy. A durable response after rituximab was more frequently observed in patients undergoing second-line therapy than those in third or later (83 versus 35 %, P = 0.01). Forty-four percent of patients experienced mild hypogammaglobulinaemia after rituximab, and no clinical infection occurred. To conclude, rituximab should be considered as an alternative treatment to splenectomy. Its efficacy and safety profile should lead us to choose this medical option therapy before surgery for ITP patients.
Subject(s)
Purpura, Thrombocytopenic, Idiopathic/drug therapy , Rituximab/therapeutic use , Salvage Therapy/methods , Adolescent , Adult , Aged , Aged, 80 and over , Dysgammaglobulinemia/chemically induced , Humans , Middle Aged , Purpura, Thrombocytopenic, Idiopathic/surgery , Retrospective Studies , Rituximab/adverse effects , Salvage Therapy/standards , Splenectomy , Treatment Outcome , Young AdultABSTRACT
After failure of erythropoiesis-stimulating agents (ESAs), lenalidomide (LEN) yields red blood cell (RBC) transfusion independence (TI) in 20-30% of lower-risk non-del5q myelodysplastic syndrome (MDS). Several observations suggest an additive effect of ESA and LEN in this situation. We performed a randomized phase III study in 131 RBC transfusion-dependent (TD, median transfusion requirement six RBC units per 8 weeks) lower-risk ESA-refractory non-del5q MDS. Patients received LEN alone, 10 mg per day, 21 days per 4 weeks (L arm) or LEN (same schedule) + erythropoietin (EPO) beta, 60,000 U per week (LE arm). In an intent-to-treat (ITT) analysis, erythroid response (HI-E, IWG 2006 criteria) after four treatment cycles (primary end point) was 23.1% (95% CI 13.5-35.2) in the L arm and 39.4% (95% CI 27.6-52.2) in the LE arm (P=0.044), while RBC-TI was reached in 13.8 and 24.2% of the patients in the L and LE arms, respectively (P=0.13). Median response duration was 18.1 and 15.1 months in the L and LE arms, respectively (P=0.47). Side effects were moderate and similar in the two arms. Low baseline serum EPO level and a G polymorphism of CRBN gene predicted HI-E. Combining LEN and EPO significantly improves erythroid response over LEN alone in lower-risk non-del5q MDS patients with anemia resistant to ESA.
Subject(s)
Blood Transfusion , Chromosome Deletion , Chromosomes, Human, Pair 5/genetics , Erythropoietin/therapeutic use , Myelodysplastic Syndromes/drug therapy , Thalidomide/analogs & derivatives , Aged , Anemia/prevention & control , Angiogenesis Inhibitors/therapeutic use , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Lenalidomide , Male , Middle Aged , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/pathology , Neoplasm Staging , Prognosis , Prospective Studies , Risk Factors , Thalidomide/therapeutic useABSTRACT
INTRODUCTION: The diagnosis of the antiphospholipid syndrome (APS) is based on clinical and biological criteria including the persistent presence of antiphospholipid antibodies and thrombotic events or pregnancy morbidity. Heparins relayed by vitamin K antagonists (VKA) are the gold standard treatment for thrombosis. CASE REPORT: We report a 17-year-old man who presented with an initially seronegative antiphospholipid syndrome, in whom the diagnosis was late, only obtained after anticoagulation withdrawing, when a catastrophic antiphospholipid syndrome (CAPS) with cutaneous lesions and disseminated intravascular coagulation syndrome occurred. For personal convenience, this patient was initially treated with fondaparinux followed by a new oral anticoagulant (rivaroxaban) before to return to the conventional VKA treatment. CONCLUSION: The "seronegative" APS is a controversial concept reflecting the heterogeneity of antigenic targets for aPL. This diagnosis may be considered after a rigorous work-up, with the help of haemostasis laboratories testing new emerging aPL assays. In APS, the new anticoagulants represent an attractive option needing nevertheless prospective studies to evaluate their safety and efficacy. Lupus anticoagulant detection in patients treated by new oral anticoagulants is not easy by usually recommended coagulation tests.
Subject(s)
Antibodies, Antiphospholipid/blood , Antiphospholipid Syndrome/diagnosis , Antiphospholipid Syndrome/drug therapy , Disseminated Intravascular Coagulation/etiology , Adolescent , Anticoagulants/therapeutic use , Disseminated Intravascular Coagulation/drug therapy , Factor Xa Inhibitors/therapeutic use , Fondaparinux , Humans , Male , Morpholines/therapeutic use , Polysaccharides/therapeutic use , Rivaroxaban , Thiophenes/therapeutic useABSTRACT
To avoid repeated apheresis, the objective of this study was to analyse the predictive factors for a single successful cytapheresis during the first mobilisation. The pre-collection characteristics of 170 lymphoma and 95 myeloma patients were analysed. Among 60 lymphoma patients who had less than 30 CD34 cells/mm(3) the day before the first apheresis, an increase in the CD34 cell count between Day -1 and Day 1 was predictive of first stem cell mobilisation success, with a sensitivity of 100% if the Day 1 was higher than 30/mm(3) (10/60 patients). Success rate of obtaining an appropriate number of stem cells in one apheresis was 120 among 170 patients.
Subject(s)
Cytapheresis/methods , Hematopoietic Stem Cell Mobilization/methods , Lymphoma/diagnosis , Lymphoma/therapy , Multiple Myeloma/diagnosis , Multiple Myeloma/therapy , Adult , Aged , Antigens, CD34/blood , Cohort Studies , Female , Hematopoietic Stem Cell Transplantation , Humans , Lymphoma/blood , Male , Middle Aged , Multiple Myeloma/blood , Predictive Value of Tests , Prognosis , Transplantation Conditioning/methods , Transplantation, Autologous , Treatment Outcome , Young AdultABSTRACT
Campylobacter has been associated with immunoproliferative small intestinal disease (IPSID), on the basis of 16S rDNA sequencing, in situ hybridization, and immunohistochemistry. Here, for the first time, we have cultured Campylobacter from the stools of a patient with IPSID. Phenotypic analysis and whole genome sequencing identified Campylobacter coli. PCR on a IPSID tissue biopsy sample was positive for Campylobacter coli and negative for Campylobacter jejuni. These findings further support a causative role for Campylobacter in the development of IPSID.
Subject(s)
Campylobacter coli/isolation & purification , Feces/microbiology , Immunoproliferative Small Intestinal Disease/microbiology , Sequence Analysis, DNA , Adult , Campylobacter coli/genetics , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Genome, Bacterial , Histocytochemistry , Humans , Immunohistochemistry , Immunoproliferative Small Intestinal Disease/pathology , Male , Microscopy , Positron-Emission Tomography , Radiography, AbdominalABSTRACT
A large proportion of lower-risk myelodysplastic syndromes (MDS) respond to erythropoiesis-stimulating agents (ESA), but most responses are transient. We updated a previously reported cohort of lower-risk MDS patients treated with ESA and analyzed outcomes after ESA failure. In 120 patients with primary resistance and 66 patients with relapse after an initial response to ESA, the 5-year cumulative incidence of acute myeloid leukemia (AML) after failure was 18.9% and 11.6%, respectively (P=0.20). Median overall survival (OS) after failure was 40.1 and 44.9 months (P=0.35), respectively. We further categorized patients as 'early failures' (including resistance and relapse after <6 months of response), or 'later failures' (that is, relapse after ≥6 months). The 5-year cumulative incidence of AML and median OS after failure in early and later failure were 21.6% and 9% (P=0.02) and 36.7 and 54.3 months (P=0.02), respectively. Early failure to ESA and a baseline diagnosis of refractory anemia with excess blasts (RAEB)-1 were independent prognostic factors for AML progression and, along with trisomy 8, for shorter OS. Median OS from treatment onset was 40, 90.7 and 65.8 months in early failure, later failure and no relapse, respectively (P=0.001). Lower-risk MDS with early failure to ESA have a relatively unfavorable outcome, and should be offered alternative treatments.
Subject(s)
Anemia/complications , Chromosomes, Human, Pair 5 , Hematinics/therapeutic use , Myelodysplastic Syndromes/drug therapy , Female , Humans , Male , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/genetics , Recurrence , Treatment OutcomeABSTRACT
Darbepoetin (DAR), with or without granulocyte colony-stimulating factor (G-CSF), has proved effective in treating anemia in patients with lower-risk myelodysplastic syndrome (MDS), but its effects on quality of life (QoL) and exercise functioning are less well established. In this phase II study (no. NCT00443339), lower-risk MDS patients with anemia and endogenous erythropoietin (EPO) level <500 IU/L received DAR 500 µg once every 2 weeks for 12 weeks, with G-CSF added at week 12 in non-responders. Physical performance was assessed with the 6-min walking test and, for fit patients, maximal oxygen consumption (VO2max). QoL was evaluated using SF-36 and FACT-An tests. In 99 patients, erythroid response rate according to IWG 2006 criteria was 48 and 56 % at 12 and 24 weeks, respectively. Addition of G-CSF rescued 22 % of non-responders. In 48 % of the responders, interval between darbepoetin injections could be increased for maintenance treatment. Serum EPO level was the only independent predictive factor of response at 12 weeks, and its most discriminant cutoff value was 100 IU/L. QoL and VO2max showed improvement over time in responders, compared with non-responders. With a median follow-up of 52 months, median response duration was not reached, and 3-year cumulative incidence of acute myeloid leukemia and overall survival (OS) was 14.5 and 70 %, respectively. Baseline transfusion dependence, International Prognostic Score System (IPSS), and Revised IPSS accurately predicted OS from treatment onset. Tolerance of darbepoetin was good. In conclusion, this regimen of darbepoetin every 2 weeks yielded high response rates and prolonged response duration. Objective improvement in exercise testing and in patient-reported QoL confirms the clinical relevance of anemia correction with erythropoiesis-stimulating agents.
Subject(s)
Erythropoietin/analogs & derivatives , Exercise Tolerance/drug effects , Granulocyte Colony-Stimulating Factor/administration & dosage , Myelodysplastic Syndromes/drug therapy , Quality of Life , Aged , Anemia/complications , Anemia/drug therapy , Anemia/mortality , Anemia/physiopathology , Darbepoetin alfa , Erythropoietin/administration & dosage , Erythropoietin/adverse effects , Exercise/physiology , Female , Filgrastim , Granulocyte Colony-Stimulating Factor/adverse effects , Hematinics/administration & dosage , Hematinics/adverse effects , Humans , Male , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/mortality , Myelodysplastic Syndromes/physiopathology , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Risk , Survival Analysis , Treatment OutcomeSubject(s)
Hospitalization/economics , Neoplasms/economics , Stem Cell Transplantation/economics , Female , Humans , MaleABSTRACT
We evaluated the prognostic value of serum ferritin (SF) level at diagnosis in 318 newly diagnosed IPSS low and int 1 (lower) risk MDS patients included in the French MDS registry, who did not require RBC transfusions and had baseline SF level determination. Increased baseline SF level (>300 ng/ml) was correlated with male gender, more pronounced anaemia, and diagnosis of RARS but had no negative impact on progression to AML or survival.
Subject(s)
Blood Transfusion , Ferritins/metabolism , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/mortality , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Myelodysplastic Syndromes/blood , Prognosis , Risk Factors , Survival RateABSTRACT
Pulmonary oedemas occurring during or after a blood transfusion appear as the most frequent serious immediate incidents in the French hemovigilance database. They include transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI). TACO are a major cause of transfusion-related death in France. TRALI are more and more recognized and notified. In no case, pooled fresh frozen plasma (100 donations) treated with solvent-detergent were involved in French TRALI cases. A logigrame will allow hemovigilance officers to better classify pulmonary oedemas in e-fit, the French hemovigilance database.
Subject(s)
Acute Lung Injury/etiology , Pulmonary Edema/etiology , Transfusion Reaction , Acute Lung Injury/diagnosis , Acute Lung Injury/physiopathology , Humans , Pulmonary Edema/diagnosis , Pulmonary Edema/physiopathologyABSTRACT
Erythropoiesis-stimulating agents (ESAs) remain the first-line treatment of anemia in lower risk myelodysplastic syndromes (MDS) without 5q deletion. A preliminary report suggested that adding all-trans retinoic acid (ATRA) to ESAs may improve their erythroid response, particularly in patients with high endogenous erythropoietin (EPO) level, and may improve other cytopenias. We conducted a prospective multicenter study of EPO-beta and ATRA in anemic MDS patients with marrow blasts <10% and either previous ESA failure or relapse, endogenous EPO >500 U/l or other cytopenia(s) (absolute neutrophilic count <1.0 G/l or platelets <50 G/l). A total of 59 patients were evaluable after 12 weeks of treatment. The erythroid response rates according to IWG 2000 and 2006 criteria, respectively, were as follows: overall: 49 and 36%; patients with previous ESA failure (n=28): 43 and 32%; patients with endogenous EPO >500 U/l (n=18): 11 and 19%; patients transfused >2 red blood cells units/month (n=28) 43 and 39%. Only one neutrophil, but no platelet response, and no major side effect were observed. EPO-beta-ATRA combination appears a possible therapeutic option in anemia of MDS having failed an ESA alone, but not in patients with high endogenous EPO level, and does not improve neutropenia and thrombocytopenia.
Subject(s)
Erythropoietin/therapeutic use , Myelodysplastic Syndromes/drug therapy , Tretinoin/therapeutic use , Adult , Aged , Aged, 80 and over , Drug Therapy, Combination , Female , Humans , Leukocyte Count , Male , Middle Aged , Neutropenia/drug therapy , Neutrophils , Platelet Count , Recombinant Proteins , Thrombocytopenia/drug therapy , Treatment Outcome , Young AdultABSTRACT
An open-label, phase II non-randomised trial was conducted with darbepoetin (DAR), an erythropoiesis-stimulating factor with prolonged half-life, at a weekly dose of 300 mug subcutaneously in 62 anaemic patients with myelodysplastic syndrome (MDS) with an endogenous erythropoietin (EPO) level <500 mU/ml. Most of the patients were classified as low or intermediate 1 according to the International Prognostic Scoring System. After 12 weeks, 44 (71%) patients had an erythroid response (34 major and 10 minor), including eight of 13 patients who were previous non-responders to conventional EPO. Two additional responses (one minor and one major) occurred, in 10 non-responders, after the addition of granulocyte colony-stimulating factor (G-CSF). Thirty-six of the 46 total responders (31/35 major and 5/11 minor) continued to respond on maintenance DAR after a median of 40 weeks (range 4-84). Median dose of DAR required to maintain response was 300 microg every 14 d. The only prognostic factors of favourable response were low endogenous EPO level and low or absent red blood cell transfusion requirement. Those results suggest that high-dose DAR alone yields high erythroid response rates in anaemia of lower risk MDS, possibly equivalent to those obtained with conventional EPO + G-CSF, although this will need to be confirmed in larger and randomised trials.
Subject(s)
Anemia/drug therapy , Erythropoietin/analogs & derivatives , Myelodysplastic Syndromes/complications , Aged , Aged, 80 and over , Anemia/complications , Darbepoetin alfa , Drug Administration Schedule , Drug Therapy, Combination , Erythropoiesis/drug effects , Erythropoietin/administration & dosage , Erythropoietin/adverse effects , Erythropoietin/therapeutic use , Female , Granulocyte Colony-Stimulating Factor/administration & dosage , Humans , Injections, Subcutaneous , Male , Middle Aged , Myelodysplastic Syndromes/drug therapy , Risk Factors , Treatment OutcomeABSTRACT
A 32-year-old patient taking corticosteroid therapy for 10 months for autoimmune hemolytic anemia developed Hodgkin's disease and concomitant acute pulmonary nocardiosis. After treatment with imipenen and amikacin for 15 days, which was adapted to susceptibility tests, multiple-drug chemotherapy using the ABVD protocol (doxorubicin, bléomycin, vinblastine, dacarbazine) was given without recurrence of the pulmonary infection. Antibiotic prophylaxis using a minocycine-erythromycin combination was continued for 8 months. We discuss the importance of long-term treatment based on data in the literature.
Subject(s)
Drug Therapy, Combination/therapeutic use , Hodgkin Disease/drug therapy , Lung Diseases/drug therapy , Nocardia Infections/drug therapy , Adult , Amikacin/administration & dosage , Anemia, Hemolytic/complications , Anemia, Hemolytic/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Erythromycin/administration & dosage , Hodgkin Disease/complications , Humans , Imipenem/administration & dosage , Long-Term Care , Lung Diseases/etiology , Male , Minocycline/administration & dosage , Nocardia Infections/complicationsABSTRACT
We describe the cytogenetic findings of three cases with simultaneous or sequential development of a B-chronic lymphocytic leukemia (B-CLL) and either a myelodysplastic syndrome (MDS) in 2 cases or a chronic myeloid leukemia (CML) in one case. The coexistence of these two hematologic malignancies leads to questions about their cell of origin. Through analysis of the cytogenetic abnormalities, we studied the derivation of both malignancies. The cytogenetic analyses of these three patients were simultaneously studied from both peripheral blood and bone marrow. Furthermore unstimulated short-time (USSTC) and long-time (72-96 hours) stimulated cultures (LTSC) were systematically performed. In all cases, we have demonstrated the independent bi-clonal evolution. This is the first report ever described for patients with CLPD and MDS and/or MPD shown to arise from distinct chromosomal abnormalities.
Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Myelodysplastic Syndromes/complications , Aged , Cell Lineage/genetics , Chromosome Aberrations , Clone Cells/pathology , Cytogenetic Analysis , Female , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Male , Middle Aged , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/pathology , Neoplasms, Second Primary/genetics , Neoplasms, Second Primary/pathologyABSTRACT
Drug-induced cytopenias are sometimes related to the so-called immuno-allergic mechanism which involves an unusual and unpredictable (i.e.: allergic) immune mediated reaction against the drug, leading to the cell-lysis of either peripheral blood granulocytes, thrombocytes; or erythrocytes. Agranulocytosis is typically induced by amidopyrine, whereas thrombocytopenia and hemolytic anemia are observed with drugs like quinine-quinidine, betalactams antibiotics, sulfonamides, rifampicin etc. In vitro methods for identification of the offending drug are cumbersome and poorly suitable for routine use. Therefore, definite diagnosis in these cases is first based on clinical and hematological grounds. These accidents recover spontaneously. However, potentially severe complications (infection, bleeding) deserve to prevent the risk of recurrence by a lifetime prohibition of the identified or suspected drug.
Subject(s)
Agranulocytosis/chemically induced , Agranulocytosis/immunology , Drug Hypersensitivity/immunology , Thrombocytopenia/chemically induced , Thrombocytopenia/immunology , Agranulocytosis/physiopathology , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/immunology , Antimalarials/adverse effects , Antimalarials/immunology , Diagnosis, Differential , Humans , Lactams , Quinidine/adverse effects , Quinidine/immunology , Quinine/adverse effects , Quinine/immunology , Recurrence , Risk Factors , Thrombocytopenia/physiopathologyABSTRACT
INTRODUCTION: Persistent polyclonal B-cell lymphocytosis is a rare hematological disorder, characterized by a chronic, stable and absolute polyclonal lymphocytosis, the presence of binucleated lymphocytes, a polyclonal increase in serum IgM immunoglobulin and clonal cytogenetic abnormalities involving chromosome 3. For explaining the expansion of B-lymphocytes pool in PPBL, an association with cigarette smoking and/or chronic Epstein-Barr virus infection have been suggested but both hypotheses have been ruled out. MATERIALS AND METHODS: We studied the presence of BCL-2/IgH rearrangements in a series of eight PPBL patients (seven females and one male) by a nested polymerase chain reaction (PCR), targeting the Major Breakpoint Region in BCL-2 locus and we explored the BCL-2 protein expression by Western blot. RESULTS: We demonstrated: (a) the constant presence of BCL-2/IgH rearrangements in eight out of eight DNA samples, (b) multiple rearrangements in three out of eight cases and, (c) normal BCL-2 protein expression, as compared to BCL-2 level in B-lymphocytes from healthy population. CONCLUSION: Despite the presence of BCL-2/IgH rearrangements, the accumulation of B lymphocytes in PPBL is not related to an overexpression of BCL-2 protein.
Subject(s)
B-Lymphocytes/pathology , Gene Rearrangement, B-Lymphocyte/genetics , Genes, Immunoglobulin/genetics , Lymphocytosis/etiology , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , Adult , B-Lymphocytes/metabolism , Base Sequence , Blotting, Western , Female , Humans , Lymphocytosis/pathology , Male , Middle Aged , Polymerase Chain ReactionABSTRACT
The clinical impact of gallium-67 scintigraphy before and after therapy for lymphoma remains controversial. The aims of this study were: (1) to compare the staging of lymphoma by 67Ga scintigraphy only with staging by clinical examination and conventional imaging (CI), and (2) to analyse the clinical relevance of both 67Ga imaging and CI after treatment. From March 1995 to November 1998, 86 67Ga scintigraphy studies were performed in 62 patients with Hodgkin's disease (n=52) or non-Hodgkin's lymphoma (n=10). 67Ga scintigraphy was performed at diagnosis (n=44) or after therapy (n=42) using 185-220 MBq 67Ga citrate and planar and single-photon emission tomography (SPET) studies. Treatment comprised radiotherapy, chemotherapy or combined modalities. CI included plain chest radiography, computed tomography (CT) of the chest and abdomen/pelvis, ultrasound of the abdomen, lymphography, bone marrow biopsy and, when necessary, magnetic resonance imaging (MRI) and bone scintigraphy. For individual suspected sites of disease before treatment, complete agreement between clinical examination and CI on the one hand and 67Ga scintigraphy on the other hand was observed in 25/44 patients (57%; 95% confidence interval 41%-72%). Clinical examination and CI showed more sites than did 67Ga scintigraphy in 12/44 patients (27%) and 67Ga imaging demonstrated more sites than CI in 6/44 patients (11%). The clinical stage of the disease as assessed using 67Ga scintigraphy only was in agreement with that using all diagnostic procedures in 34/44 patients (77%; 95% confidence interval 62%-89%). Compared with CI staging, 67Ga scintigraphy downstaged seven patients (16%) and upstaged three (7%). 67Ga scintigraphy downstaged mainly because of the limited value of the technique below the diaphragm and upstaged owing to the good sensitivity in the lung. After therapy, both CI and 67Ga scintigraphy were normal in 11 patients. All but one of these patients were in complete remission after a median follow-up of 31 months. In contrast, radiological residual mass was observed in 31/42 patients. 67Ga imaging was normal in 22/31 (71%); 17 of these 22 patients, including nine with a large residual mass (> or =2 cm), were in complete remission after a median follow-up of 32 months, while four suffered relapses 8-45 months later. The cause of death remained unknown in one patient. 67Ga scintigraphy showed abnormal uptake in 9 of the 31 patients with a large residual mass. Active disease was demonstrated in eight patients and one patient was in complete remission 30 months thereafter. Our data show that 67Ga imaging cannot replace CI in initial staging but can demonstrate additional individual sites of disease in more than 10% of patients and can lead to clinical upstaging with potential prognostic and therapeutic consequences. After therapy, 67Ga scintigraphy has a clinical impact when radiological abnormalities persist because it can either avoid unnecessary complementary treatment or confirm the need to change treatment modalities.
Subject(s)
Citric Acid , Gallium Radioisotopes , Hodgkin Disease/diagnostic imaging , Lymphoma, Non-Hodgkin/diagnostic imaging , Female , Follow-Up Studies , Hodgkin Disease/pathology , Hodgkin Disease/therapy , Humans , Lymphoma, Non-Hodgkin/pathology , Lymphoma, Non-Hodgkin/therapy , Male , Neoplasm Staging , Time Factors , Tomography, Emission-Computed, Single-PhotonABSTRACT
PURPOSE: To identify the prognostic factors that influence overall survival (OS) in patients with stage III-IV follicular lymphomas and evaluate the clinical usefulness and the prognostic value of the International Prognostic Index (IPI). PATIENTS AND METHODS: Four hundred eighty-four patients with Ann Arbor stage III-IV follicular lymphomas treated in two phase III trials from 1986 to 1995 were screened for this study. All histologic slides were reviewed by two hematopathologists. The influence of the initial parameters on survival was defined by univariate (log-rank test) and multivariate (Cox model) analyses. RESULTS: The poor prognostic factors for OS (age > 60 years, "B" symptom(s), > or = two extranodal sites, stage IV disease, tumor bulk > 7 cm, at least three nodal sites > 3 cm, liver involvement, serous effusion-compression or orbital/epidural involvement, and erythrocyte sedimentation rate > 30 mm/h) that were significant in univariate analysis were subjected to multivariate analysis. Three factors remained significant: B symptom(s) (risk ratio = 1.80), age greater than 60 years (risk ratio = 1.60), and at least three nodal sites greater than 3 cm (risk ratio = 1.71). When the IPI was applied to these patients, the score was 1, 2, 3, and 4-5 in 49%, 39%, 11%, and 2%, respectively, and it was significant for progression-free survival (P =.002) and OS (P =.0001). CONCLUSION: Three prognostic factors for poor OS were identified: B symptoms, age greater than 60 years, and at least three nodal sites greater than 3 cm. The IPI was prognostic for OS, but in this population, a very low number of patients belonged to the high-risk groups.